Klin Farmakol Farm. 2007;21(3):133-136

Clinical significance of cytochrome P4502D6

Jana Ďuricová, Milan Grundmann
Ústav klinické farmakologie FNsP a ZSF Ostravské univerzity, Ostrava

The enzymes of the cytochrome P450 are the major enzymes responsible for metabolizing of drugs. The CYP2D6 is highly polymorphic enzyme and shows a very high degree of interindividual variability. The CYP2D6 metabolizes approximately 25 % of all medications. Many studies point out the significant influence of CYP2D6 on pharmacokinetics and pharmacodynamics of drugs.

Keywords: CYP2D6, polymorphism, phenotype

Published: January 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ďuricová J, Grundmann M. Clinical significance of cytochrome P4502D6. Klin Farmakol Farm. 2007;21(3):133-136.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol. 2004 Jan; 369: 23-37. Go to original source... Go to PubMed...
    2. Mičuda S, Martinková J, Chládek J, et al. Význam polymorfismu metabolismu léčiv v moderní farmakoterapii. Remedia 1998; 8: 226-236.
    3. Bernard S, Neville KA, Nguyen AT, et al. Interethnic differences in genetic polymorphisms of CYP2D6 in the U. S. population: Clinical Implications. Oncologist 2006; 11: 126-135. Go to original source... Go to PubMed...
    4. Cascorbi I. Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication. Eur J Clin Invest 2003; 33: 17-22. Go to original source... Go to PubMed...
    5. Steimer W, Zöpf K, von Amelunxen S, et al. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP 2C19 and CY 2D6 extensive and intermediate metabolizers. Clin Chem 2004; 50: 1623-1633. Go to original source... Go to PubMed...
    6. Lovlie R, Daly AK, Matre GE, et al. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism. Pharmacogenetics 2001; 11: 45-55. Go to original source... Go to PubMed...
    7. Bertilsson L. Geographical/Interracial differences in polymorphic drug oxidation. Clin Pharmacokinet 1995; 29: 192-209. Go to original source... Go to PubMed...
    8. Stamer MU, Lehnen K, Höthker F, et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 2003; 105: 231-238. Go to original source... Go to PubMed...
    9. Wang GX, Zhang H, He FF, et al. Effect of the CYP2D6*10 C188T polymorphism on postoperative tramadol analgesia in a Chinese population. Eur J Clin Pharmacol 2006; 62: 927-931. Go to original source... Go to PubMed...
    10. Fagerlund TH, Braaten O. No pain relief from codeine...? Acta Anaesthesiol Scand 2001; 45: 140-149. Go to original source... Go to PubMed...
    11. Kaiser R, Sezer O, Papies A, et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 2002; 20: 2805-2811. Go to original source... Go to PubMed...
    12. Janicki PK, Schuler HG, Jarzembowski TM, et al. Prevention of postoperative nausea and vomiting with granisetron and dolasetron in relation to CYP2D6 genotype. Anesth Analg 2006; 102: 1127-1133. Go to original source... Go to PubMed...
    13. Candiotti KA, Birnbach DJ, Lubarsky DA, et al. The impact of pharmacogenomics on postoperative nausea and vomiting. Anesthesiology 2005; 102: 543-549. Go to original source... Go to PubMed...
    14. Frueh FW, Gurwitz D. From pharmacogenetics to personalized medicine: a vital need for educating health professionals and community. Pharmacogenomics 2004; 5: 571-579. Go to original source... Go to PubMed...
    15. Thuerauf N, Lunkenheimer J. The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants. Eur Arch Psychiatry Clin Neurosci 2006; 256: 287-293. Go to original source... Go to PubMed...
    16. Grasmäder K, Verwohlt PL, Rietschel M, et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol 2004; 60: 329-336. Go to original source... Go to PubMed...
    17. Sawamura K, Suzuki Y, Someya T, et al. Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine. Eur J Clin Pharmacol 2004; 60: 553-557. Go to original source... Go to PubMed...
    18. Güzey C, Spigset O. Low serum concentrations of paroxetine in CYP2D6 ultrarapid metabolizers. J Clin Psychopharmacol 2006; 26: 211-212. Go to original source... Go to PubMed...
    19. Mancama D, Kerwin RW. Role of pharmacogenetics in individualising treatment with SSRIs. CNS Drugs 2003; 17: 143-151. Go to original source... Go to PubMed...
    20. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004; 9: 442-473. Go to original source... Go to PubMed...
    21. Tamminga WJ, Wemer J, Oosterhuis B, et al. Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study. Eur J Clin Pharmacol 2003; 59: 57-64. Go to original source... Go to PubMed...
    22. Jaanson P, Marandi T, Kiivet RA, et al. Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype. Psychopharmacology 2002; 162: 67-73. Go to original source... Go to PubMed...
    23. Brockmöller J, Kirchheiner J, Schmider J, et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 2002; 72: 438-452. Go to original source... Go to PubMed...
    24. Ohnuma T, Shibata N, Matsubara Y, et al. Haloperidol plasma concentration in Japanese psychiatric subjects with gene duplication of CYP2D6. Br J Clin Pharmacol 2002; 56: 315-320. Go to original source... Go to PubMed...
    25. Scordo MG, Spina E, Romeo P, et al. CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients. Eur J Clin Pharmacol 2000; 56: 679-683. Go to original source... Go to PubMed...
    26. Ismail R, Teh LK. The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients. J Clin Pharm Ther 2006; 31: 99-109. Go to original source... Go to PubMed...
    27. Nozawa T, Taguchi M, Tahara K, et al. Influence of CYP2D6 genotype on metoprolol plasma concentration and ß-adrenergic inhibition during long-term treatment. A comparison with bisoprolol. J Cardiovasc Pharmacol 2005; 46: 713-720. Go to original source... Go to PubMed...
    28. Wuttke H, Rau T, Heide R, et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-assiciated adverse effects. Clin Pharmacol Ther 2002; 72: 429-437. Go to original source... Go to PubMed...
    29. Fux R, Mörike K, Pröhmer AMT, et al. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: A prospective clinical study. Clin Pharmacol Ther 2005; 78: 378-387. Go to original source... Go to PubMed...
    30. Zineh I, Beitelshees AL, Gaedigk A, et al. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther 2004; 76: 536-544. Go to original source... Go to PubMed...
    31. Mörike K, Magadum S, Mettang T, et al. Propafenone in a usual dose produces severe sideeffects: the impact of genetically determined metabolic status on drug therapy. J Intern Med1995; 238: 469-472. Go to original source... Go to PubMed...
    32. Siddoway LA, Thompson KA, McAllister B, et al. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 1987; 75: 785-791. Go to original source... Go to PubMed...
    33. Roden DM. Genetic polymorphisms, drugs and proarrhythymia. J Interv Card Electrophysiol 2003; 9: 131-135. Go to original source... Go to PubMed...
    34. Cai WM, Xu J, Chen B, et al. Effect of CYP2D6*10 genotype on propafenone pharmacodynamics in Chinese patients with ventricular arrhythmia. Acta Pharmacol Sin 2002; 23: 1040-1044.
    35. Rae JM, Goetz MP, Hayes DF, et al. CYP2D6 genotype and tamoxifen response. Breast Cancer Res 2005; 7: 6. Go to original source... Go to PubMed...
    36. Christensen M, Andersson K, Dalén P, et al. The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther 2003; 73: 517-528. Go to original source... Go to PubMed...
    37. Frye RF. Probing the world of cytochrome P450 enzymes. Mol Interv 2004; 4: 157-162.
    38. Zhou H, Tong Z, McLeod JF., ,Cocktail" approaches and strategies in drug development: valuable tool or flawed science? J Clin Pharmacol 2004; 44: 120-134. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.